The integration of allometry and virtual populations to predict clearance and clearance variability in pediatric populations over the age of 6 years

Clinical Pharmacokinetics

Volumn 52, Issue 8, 2013, Pages 693-703

  Edginton, Andrea N ^a   Shah, Bhavank ^a   Sevestre, Michael ^b   Momper, Jeremiah D ^c  

^a UNIVERSITY OF WATERLOO   (Canada)

^b Design2Code Inc   (Canada)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; ALMOTRIPTAN; AMOXICILLIN PLUS CLAVULANIC ACID; ANASTROZOLE; ARIPIPRAZOLE; AZITHROMYCIN; CASPOFUNGIN; CELECOXIB; DIDANOSINE; EMTRICITABINE; EPLERENONE; ESCITALOPRAM; ETIRACETAM; GADOBENATE DIMEGLUMINE; GLIMEPIRIDE; LEFLUNOMIDE; LINEZOLID; LOPINAVIR PLUS RITONAVIR; MELOXICAM; NELFINAVIR; OSELTAMIVIR; PALIPERIDONE; PANTOPRAZOLE; PARACETAMOL; PEMETREXED; QUETIAPINE; RABEPRAZOLE; ROCURONIUM; UNINDEXED DRUG; ZOLEDRONIC ACID;

ACCURACY; ADOLESCENT; ADULT; ALLOMETRY; ANALYTICAL ERROR; ARTICLE; BODY SURFACE; BODY WEIGHT; CHILD; CONTROLLED STUDY; DRUG CLEARANCE; FEMALE; GROUPS BY AGE; HUMAN; INTERMETHOD COMPARISON; MALE; PREDICTION; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZATION; SCHOOL CHILD; VIRTUAL REALITY;

ADOLESCENT; ADULT; BODY WEIGHTS AND MEASURES; CHILD; CHILD, PRESCHOOL; COMPUTER SIMULATION; DATABASES, FACTUAL; FEMALE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; YOUNG ADULT;

EID: 84880836066     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-013-0065-6     Document Type: Article

References (27)

1. Wang Y, Jadhav PR, Lala M, Gobburu JV. Clarification on precision criteria to derive sample size when designing pediatric pharmacokinetic studies. J Clin Pharmacol. 2012;52:1601-6.
2. US FDA. Medical, statistical, and clinical pharmacology reviews of pediatric studies conducted under Section 505A and 505B of the Federal Food, Drug, and Cosmetic Act (the Act), as amended by the FDA Amendments Act of 2007 (FDAAA). http://www.fda.gov/Drugs/DevelopmentApprovalProcess/ DevelopmentResources/ucm049872.htm. Accessed 1 Sept 2012.
3. US FDA. Summaries of medical and clinical pharmacology reviews - summaries of medical and clinical pharmacology reviews as of 15 Jan 2008. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/ ucm161894.htm. Accessed 1 Sept 2012.
4. Third National Health and Nutrition Examination Survey, (NHANES III). 1997. National Center for Health Statistics Hyattsville, MD 20782. http://www.cdc.gov/nchs/nhanes.htm.
5. Willmann S, Hohn K, Edginton A, Sevestre M, Solodenko J, Weiss W, et al. Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs. J Pharmacokinet Pharmacodyn. 2007;34:401-31.
6. Du Bois D, Du Bois EF. A formula to estimate the approximate surface area if height and weight be known. 1916. Nutrition. 1989;5:303-11.
7. Haycock GB, Schwartz GJ, Wisotsky DH. Geometric method for measuring body surface area: a height-weight formula validated in infants, children, and adults. J Pediatr. 1978;93:62-6.
8. Johnson TN, Rostami-Hodjegan A, Tucker GT. Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clin Pharmacokinet. 2006;45:931-56.
9. Graves RE. Accuracy of regression equation prediction across the range of estimated premorbid IQ. J Clin Exp Neuropsychol. 2000;22:316-24.
10. Holford NH, Buclin T. Safe and effective variability - a criterion for dose individualization. Ther Drug Monit. 2012;34:565-8.
11. Edginton AN, Fotaki N. Oral drug absorption in pediatric populations. Oral drug absorption: prediction and assessment, 2nd ed. New York: Informa Healthcare; 2010.
12. Edginton AN, Willmann S. Physiology-based versus allometric scaling of clearance in children; an eliminating process based comparison. Paed Perinat Drug Ther. 2006;7:146-53.
13. Anderson BJ. Pediatric models for adult target-controlled infusion pumps. Paediatr Anaesth. 2010;20:223-32.
14. Mahmood I. Prediction of drug clearance in children: impact of allometric exponents, body weight, and age. Ther Drug Monit. 2007;29:271-8.
15. Anderson BJ, Holford NH. Tips and traps analyzing pediatric PK data. Paediatr Anaesth. 2011;21:222-37.
16. Jones VM. Acetaminophen injection: a review of clinical information. J Pain Palliat Care Pharmacother. 2011;25:340-9.
17. Yu J, He J, Zhang Y, Qin F, Xiong Z, Li F. An ultraperformance liquid chromatography-tandem mass spectrometry method for determination of anastrozole in human plasma and its application to a pharmacokinetic study. Biomed Chromatogr. 2011;25:511-6.
18. Mallikaarjun S, Salazar DE, Bramer SL. Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers. J Clin Pharmacol. 2004;44:179-87.
19. Ravis WR, Reid S, Sica DA, Tolbert DS. Pharmacokinetics of eplerenone after single and multiple dosing in subjects with and without renal impairment. J Clin Pharmacol. 2005;45:810-21.
20. Strolin BM, Whomsley R, Nicolas JM, Young C, Baltes E. Pharmacokinetics and metabolism of 14C-levetiracetam, a new antiepileptic agent, in healthy volunteers. Eur J Clin Pharmacol. 2003;59:621-30.
21. Burgos-Vargas R, Foeldvari I, Thon A, Linke R, Tuerck D. Pharmacokinetics of meloxicam in patients with juvenile rheumatoid arthritis. J Clin Pharmacol. 2004;44:866-72.
22. DeVane CL, Nemeroff CB. Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. Clin Pharmacokinet. 2001;40:509-22.
23. Thyrum PT, Wong YW, Yeh C. Single-dose pharmacokinetics of quetiapine in subjects with renal or hepatic impairment. Prog Neuropsychopharmacol Biol Psychiatry. 2000;24:521-33.
24. Martin PD, Warwick MJ, Dane AL, Cantarini MV. A double-blind, randomized, incomplete crossover trial to assess the dose proportionality of rosuvastatin in healthy volunteers. Clin Ther. 2003;25:2215-24.
25. Taburet AM, Naveau S, Zorza G, Colin JN, Delfraissy JF, Chaput JC, et al. Pharmacokinetics of zidovudine in patients with liver cirrhosis. Clin Pharmacol Ther. 1990;47:731-9.
26. Bergshoeff AS, Fraaij PL, Verweij C, van Rossum AM, Verweel G, Hartwig NG, et al. Plasma levels of zidovudine twice daily compared with three times daily in six HIV-1-infected children. J Antimicrob Chemother. 2004;54:1152-4.
27. Wilner KD, Hansen RA, Folger CJ, Geoffroy P. The pharmacokinetics of ziprasidone in healthy volunteers treated with cimetidine or antacid. Br J Clin Pharmacol. 2000;49(Suppl 1):57S-60S.